Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation

Lobo, Pilar Blanco; Cordero, Elisa; Martín-Gandul, Cecilia; Gentil, M.A.; Suárez-Artacho, G.; Sobrino, Manuel; Aznar, Javier; Pérez‐Romero, Pilar

doi:10.1016/j.jinf.2016.02.008

Cited by 21 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gerna et al demonstrated in healthy individuals with primary and reactivated infection that levels of neutralizing antibody able to block infection of endothelial (or epithelial) cells were higher and able to inhibit CMV plaque formation and virus transfer from CMV‐infected cells to leukocytes . A study performed by our group showed that a titer of greater than or equal to 480 for epithelial cell neutralizing antibodies correlated with decreased CMV infection, fewer days of treatment, and complete protection from CMV disease in D + /R − liver transplant recipients Allo‐HSCT setting: In the context of allo‐HSCT, defects in humoral immunity persist in the long‐term after transplantation; thus, the successful reconstitution of the immune system is important for decreasing related complications such as post‐transplant infection or graft‐versus‐host disease (GVHD).…”

Section: Introductionmentioning

confidence: 91%

“…53 A study performed by our group showed that a titer of greater than or equal to 480 for epithelial cell neutralizing antibodies correlated with decreased CMV infection, fewer days of treatment, and complete protection from CMV disease in D + /R − liver transplant recipients. 31 b. Allo-HSCT setting: In the context of allo-HSCT, defects in humoral immunity persist in the long-term after transplantation; thus, the successful reconstitution of the immune system is important for decreasing related complications such as posttransplant infection or graft-versus-host disease (GVHD). The incidence of HGG after allo-HSCT is considerable, ranging from 24% to 27% at 1 or 3 post-transplant years.…”

Section: Do Neutralizing Antibody Titers Provide Information Regardmentioning

confidence: 99%

“…In addition, up to 20% of R + SOT recipients, conventionally considered at intermediate risk, will still develop episodes of CMV infection and disease after transplantation . While lower pretransplant CMV IgG antibody titers have been significantly associated with CMV infection after liver transplantation and the IgG serostatus was predictive of subsequent CMV disease between month 6 and 12 (with incidence rates of 1.3% and 10.0% in R + and R − groups, respectively), seroconversion of R − SOT recipients did not correlate with protection from CMV infection after transplantation Allo‐HSCT setting: In this context, seropositive patients appear to display a survival disadvantage compared with their seronegative counterparts, irrespective of whether active CMV infection is documented.…”

Section: Introductionmentioning

confidence: 99%

“… SOT setting: In addition to the promising data demonstrating the clinical utility of assessing CMI for risk stratification, there is still a nonnegligible percentage of SOT recipients (ranging from 4 to 10%) with demonstrable and apparently protective CMV‐specific CMI responses that develop late‐onset disease . This observation suggests that either a higher cut‐off may be necessary for defining a positive CMV‐specific CMI response to assure that it reliably predicts protection against CMV disease, or that other arms of the immune response should also be considered. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Going beyond serology for stratifying the risk of CMV infection in transplant recipients

Navarro

Fernández‐Ruiz

Aguado

et al. 2018

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary Knowledge of donor and recipient (D/R) cytomegalovirus (CMV) serostatus is critical for risk stratification of CMV infection and disease in transplant recipients, particularly in the solid organ transplantation (SOT) setting. Despite its broad availability and the success of it use, the risk stratification based on the D/R serostatus is not free of limitations since there are a nondepreciable number of patients that are not accurately categorized by this approach. In fact, up to 20% of seropositive SOT recipients, classically considered at intermediate risk, develop episodes of CMV infection and disease after transplantation. Here, we provide an overview of additional donor and recipient factors that may have utility in identifying patients at risk for post‐transplant CMV infection. Specifically, we summarize our current understanding regarding the potential use of use CMV‐specific T‐cell‐mediated immunity, neutralizing antibodies and host genetics that may influence the risk of CMV infection and disease. We provide an overview of the benefits and limitations associated with using these immunological factors in risk stratification and propose specific variables that could be analyzed at the pretransplant evaluation to improve the identification of patients with increased individual susceptibility.

show abstract

Section: Introductionmentioning

confidence: 91%

Section: Do Neutralizing Antibody Titers Provide Information Regardmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Going beyond serology for stratifying the risk of CMV infection in transplant recipients

Navarro

Fernández‐Ruiz

Aguado

et al. 2018

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Cell mediated immune response is considered the most important arm of the immune system against CMV infection with increasing evidences demonstrating a role of CMV-specific T-cells in protecting from infection, which can contribute to improve clinical care after transplantation (19)(20)(21)(22)(23)(24)(25)(26)(27).…”

Section: Introductionmentioning

confidence: 99%

Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

et al. 2021

View full text Add to dashboard Cite

During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have an increased occurrence of CMV replication episodes and CMV-related complications. In this context, the use of adoptive transfer of CMV-specific T-cells has been widely investigated and applied to Hematopoietic Stem Cell Transplant patients and may be useful as a therapeutic alternative, to reconstitute the CMV specific T-cell response and to control CMV viremia in patients receiving a transplantation. However, only few authors have explored the use of T-cell adoptive transfer in SOT recipients. We propose a novel review in which we provide an overview of the impact of using CMV-specific T-cell adoptive transfer on the control of CMV infection in SOT recipients, the different approaches to stimulate, isolate and expand CMV-specific T-cells developed over the years and a discussion of the possible use of CMV adoptive cellular therapy in this SOT population. Given the timeliness and importance of this topic, we believe that such an analysis will provide important insights into CMV infection and its treatment/prevention.

show abstract

Evaluation of host cellular responses to Epstein–Barr virus (EBV) in adult lung transplant patients with EBV‐associated diseases

Zaffiri

Messinger

Bush

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) reactivation is commonly observed in lung transplant recipients (LTRs). However, cellular immune responses to EBV in adult LTRs have not been well described. We aimed to study CD4/CD8 ratio, EBV-specific T cells polyfunctional responses and phenotypic changes in natural killer (NK) cells in adult LTRs presenting with EBV-associated diseases. The CD4/CD8 ratio was significantly decreased in LTRs with EBV DNAemia compared with LTRs without EBV DNAemia and healthy controls (HCs). Stimulation with EBV lytic antigen BZLF1 peptide pools induced significant individual and polyfunctional responses from CD8 + CD69 + T cells.Frequencies of CD8 + CD69 + T cells expressing CD107a were significantly higher in LTRs without EBV DNAemia than in LTRs with DNAemia. Frequencies of CD8 + CD69 + T cells concurrently expressing CD107a, IFN-γ, and TNF-α were significantly greater in LTRs with and without EBV DNAemia than in HCs. Finally, BZLF1 induced significantly higher frequencies of CD8 + CD69 + T cells expressing CD107a and IFN-γ in LTRs without EBV DNAemia when compared with EBNA3B.Frequency of more differentiated CD56 dim CD16 pos NK cells was significantly decreased in LTRs with EBV DNAemia and PTLD compared with HCs. In conclusion, we noted the presence of significant changes in circulating cellular immune responses to EBV in adult LTRs.

show abstract

Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV Disease after transplantation

Cited by 21 publications

References 29 publications

Going beyond serology for stratifying the risk of CMV infection in transplant recipients

Going beyond serology for stratifying the risk of CMV infection in transplant recipients

Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Evaluation of host cellular responses to Epstein–Barr virus (EBV) in adult lung transplant patients with EBV‐associated diseases

Contact Info

Product

Resources

About